2019
DOI: 10.1080/17425247.2019.1662785
|View full text |Cite
|
Sign up to set email alerts
|

Long-term delivery of protein and peptide therapeutics for cancer therapies

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
11
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 17 publications
(12 citation statements)
references
References 138 publications
0
11
0
Order By: Relevance
“…Although small, lipophilic molecules have a higher propensity toward skin penetration, many therapeutics identified in recent times are biomolecules including DNA, RNA, proteins, and polysaccharides. In this report, we have explored the delivery of one such biomacromolecule, chondroitin sulfate (CS). CS being a negatively charged polymer with a molecular weight ranging from 15 to 50 kDa cannot diffuse passively through the skin layers because of its negative charge, hydrophilicity, and size and therefore needs active administration.…”
Section: Discussionmentioning
confidence: 99%
“…Although small, lipophilic molecules have a higher propensity toward skin penetration, many therapeutics identified in recent times are biomolecules including DNA, RNA, proteins, and polysaccharides. In this report, we have explored the delivery of one such biomacromolecule, chondroitin sulfate (CS). CS being a negatively charged polymer with a molecular weight ranging from 15 to 50 kDa cannot diffuse passively through the skin layers because of its negative charge, hydrophilicity, and size and therefore needs active administration.…”
Section: Discussionmentioning
confidence: 99%
“…Nowadays, protein-based biologically active compounds and drugs, such as hormones, antioxidants, enzymes, enzyme inhibitors, vaccines, antitumor agents, etc., have gained wide application in medicine, food industry, and biotechnology. On the other hand, their use is associated with some limitations, the main of which are related to high sensitivity of proteins and medicines to denaturation, aggregation, or hydrolysis in the gastrointestinal tract (GIT), undesirable interactions of components of a medicine with each other or with other medicines, poor absorption of proteins in the GIT, hydrophobicity, instability and degradation on storage, toxicity, and immunogenicity of foreign protein components [1][2][3][4][5]. One of the approaches to overcome these limitations is based on encapsulation of proteins using appropriate carriers [1,[6][7][8][9][10][11].…”
Section: Encapsulation Of Proteinsmentioning
confidence: 99%
“…Variable [5,181] High [5] Relatively low Inorganic matrices 22-41% [18] 1.7% [19] Up to 20% [182] 23-100% [21] 30-280 to 2000 nm [21,22,183,184] 2-3 nm to 2-3 μm [21,180,183] Yes [180] High Insufficient data (up to 15 days) [21] Variable [19,21,22,180,[183][184][185][186]] Under extensive study [21,183,186] Low Polymersomes 10-60% [187] 5 nm-5 μm [176] -Yes [188] Up to 6 months or more [167] Depends on the structure of amphiphilic block copolymer [167] Depends on the structure of amphiphilic block copolymer [188] Variable…”
Section: Lowmentioning
confidence: 99%
See 1 more Smart Citation
“…The use of nanosized formulations has been proven to be a promising strategy to alleviate some of these problems. Peptide and protein nanogels are particularly attractive as they allow to generate nanosized formulations of these biologics with essentially quantitative encapsulation efficiency. …”
Section: Introductionmentioning
confidence: 99%